Insulet’s Omnipod continues to deliver

ACTON, Mass. – Insulet Corporation reported revenue of $783.8 million for the fourth quarter of 2025, an increase of 31% over the same period a year prior and ahead of the company’s guidance in the 25% to 28% range.   

Of that, U.S. Omnipod revenue was $567.8 million and international Omnipod revenue was $214 million.  

For the full year, Insulet reported revenue of $2.7 billion, an increase of 30.7%, over the previous year. Of that, U.S. revenue was $1.9 billion and international revenue was $754.3 million.   

“We ended the year with another excellent quarter, demonstrating the power of our business model, the strength of our technology, and the disciplined execution of our team,” said Ashley McEvoy, president and CEO. “Our performance shows that Insulet continues to lead with innovation, scale, and customer trust — and that our competitive position has never been stronger. As we move into 2026, we are confident in our ability to grow the global AID market, expand adoption across type 1 and type 2 diabetes, and deliver on the strategic and financial commitments we have laid out. Insulet has the talent, the technology, and the momentum to lead this category for the long term.”  

Other highlights:  

• Achieved a significant milestone of more than 600,000 estimated active Omnipod users globally, reflecting continued adoption across U.S. and international markets.  
• Received U.S. FDA clearance for significant Omnipod 5 algorithm enhancements, delivering greater customization, tighter glucose management, and the ability for users to remain in automated mode longer—further simplifying the Pod experience.  
• Expanded Omnipod 5 U.S. recycling program, diverting millions of Pods from landfills and creating a more sustainable future.  
• Received approval from the Board of Directors for a $350 million increase in our share repurchase authorization.